Format

Send to

Choose Destination
Trends Biotechnol. 2006 Mar;24(3):99-101. Epub 2006 Jan 30.

Competitive bioreactor hens on the horizon.

Author information

1
Department of Genetics, University of Georgia, Athens, GA 30602-7223, USA. ivarie@uga.edu

Abstract

The hen has long held promise as a low-cost, high-yield bioreactor for the production of human biopharmaceuticals in egg whites using genetic engineering. Two separate reports have recently appeared indicating the production of substantial levels of human monoclonal and single chain antibodies (>3 mg and >150 mg, respectively) in eggs of transgenic hens. These promising findings indicate that the hen is close to becoming a competitive manufacturing platform for the production of human biopharmaceuticals.

PMID:
16445998
DOI:
10.1016/j.tibtech.2006.01.004
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center